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Transgenic mouse modelrole in energy metabolism in the heart. Cardiomyocytes accumulate creatine via
a speciﬁc creatine transporter (CrT), the capacity of which is reduced in the failing heart, resulting in lower
myocardial creatine concentration. Therefore, to gain insight into how the CrT is regulated, we studied two
mouse models of severely altered myocardial creatine levels. Cardiac creatine uptake levels were measured in
isolated hearts from creatine-free guanidinoacetate-N-methyl transferase knock out (GAMT−/−) mice and
from mice overexpressing the myocardial CrT (CrT-OE) using 14C-radiolabeled creatine. CrT mRNA levels
were measured using real time RT-PCR and creatine levels with HPLC. Hearts from GAMT−/− mice showed a
7-fold increase in Vmax of creatine uptake and a 1.4-fold increase in CrT mRNA levels. The increase in Cr
uptake and in CrT mRNA levels, however, was almost completely prevented when mice were fed a creatine
supplemented diet, indicating that creatine uptake is subject to negative feedback regulation. Cardiac
creatine uptake levels in CrT-OE mice were increased on average 2.7-fold, showing a considerable variation,
in line with a similar variation in creatine content. Total CrT mRNA levels correlated well with myocardial
creatine content (r=0.67; pb0.0001) but endogenous CrT mRNA levels did not correlate at all with
myocardial creatine content (r=0.01; p=0.96). This study shows that creatine uptake can be massively
upregulated in the heart, by almost an order of magnitude and that this upregulation is subject to feedback
inhibition. In addition, our results strongly suggest that CrT activity is predominantly regulated by
mechanisms other than alterations in gene expression.
© 2008 Elsevier Inc. Open access under CC BY-NC-ND license. 1. IntroductionIn tissues with a high energy demand, such as myocardium,
creatine plays an important role in energy metabolism. ATP
synthesized by the mitochondria reacts with creatine in the creatine
kinase (CK) reaction to form ADP and phosphocreatine (PCr). At the
ATP consuming site the reverse reaction takes place replenishing ATP
levels and maintaining low ADP concentrations.
Creatine originates from both dietary intake and from biosynthesis,
predominantly in the liver and kidneys. Cardiomyocytes cannot
synthesize creatine and somust accumulate it from the plasma against
a large concentration gradient via a speciﬁc Na+–creatine cotranspor-
ter (CrT) [1]. Creatine is lost from the cardiomyocyte due to
spontaneous, nonenzymatic conversion into creatinine, which is
membrane permeable and diffuses out of the cell, and, possibly, via
efﬂuxof creatine itself [1,2]. Such uptake and the resulting intracellularom E03.511, University Medical
e Netherlands. Tel.: +31 0 88
iel.tenhove@well.ox.ac.uk
is work.
-NC-ND license. creatine concentration are tightly controlled. For example, oral
creatine supplementation in rats results in elevated plasma creatine
concentration, but due to downregulation of the cardiac creatine
uptake capacity, myocardial creatine levels remain unchanged [2].
Heart failure is characterized by reduced myocardial PCr and total
creatine (Cr) levels [3,4]. We have previously shown that, in both rat
and mouse models of heart failure due to chronic coronary ligation,
the reduced myocardial creatine content can at least in part be
explained by reduced myocardial creatine uptake capacity [5] and CrT
gene expression [6].
However, little is known about how and to what extent CrT
expression and activity can be regulated and, thus on howandwhy CrT
function is downregulated in heart failure. Upregulation of uptake
capacity can be achieved via administration of the creatine analogueβ-
guanidinoproprionic acid (β-GPA), which acts as a competitive
inhibitor of the CrT [2], suggesting that intracellular creatine
concentration is an important regulating factor. A recent report
demonstrated that CrT activity can be upregulated by the serum and
glucocorticoid kinase 1 (SGK1) in Xenopus oocytes expressing the CrT
[7], but it is unknownwhether cardiac CrT is regulated in the sameway.
We recently reported the ﬁrst two genetically manipulated mouse
models of altered myocardial creatine concentration. Guanidinoace-
tate-N-methyl transferase knock out (GAMT−/−) mice are unable to
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are entirely creatine-free. Instead, these mice accumulate the creatine
precursor guanidinoacetate (GA), which is phosphorylated in the CK
reaction instead of creatine and partially takes over the role of creatine
[9]. However, the CK reaction velocity is reduced by two orders of
magnitude with GA as substrate [10]. In contrast, mice overexpressing
the cardiac CrT (CrT-OE) have elevated myocardial creatine levels [11].
The cardiac creatine uptake capacity of both these mouse models is
currently unknown. An understanding of the creatine uptake capacity
under these extreme conditions (i.e. no creatine at all and forced
increase of creatine levels) could provide important new insights into
the regulation of cardiac creatine transport.
We hypothesized that absence of creatine would trigger upregula-
tion of the cardiac creatine uptake capacity, and that overexpression of
themyocardial CrT would result in increased creatine uptake levels. To
test this, and to quantify the degree of potential CrT upregulation, we
measured the creatine uptake capacity in isolatedhearts fromGAMT −/−
and CrT overexpressing mice. In addition, we measured CrT mRNA
levels in hearts of these mice as well as protein levels of SGK1, a
candidate CrT regulator, in the hearts of GAMT−/− mice.Fig. 1. Left (A) and right (B) ventricular creatine uptake kinetics in hearts fromwildtype (WT)
n=4 or 5 per [Cr]e). (C) Creatine uptake levels in hearts from WT and GAMT−/− mice fed wi
1 mmol/L extracellular creatine. ⁎pb0.05 vs WT-Cr; ⁎⁎pb0.001 vs WT-Cr; ⁎⁎⁎pb0.05 vs GA2. Methods
2.1. Mice
GAMT−/− and wildtype (WT) littermates used for experiments were
created by intercrossing heterozygous GAMT+/− mice, as previously
described [8]. From 6 weeks of age, mice were housed per genotype to
prevent ingestion of creatine in GAMT−/−mice through coprophagia. CrT
overexpressing mice were created as described before [11]. These mice
express the rabbit CrT with a human c-myc epitope tag (CrT-myc) under
control of the murine ventricular myosin light chain 2 (MLC2v)
promoter. All transgenic mice (CrT-OE) and wildtype (WT) littermates
used in experiments were generated by mating male transgenics with
C57BL/6 females. All animals were genotyped by PCR using standard
conditions.
Micewere kept in cages with a 12 h light–dark cycle and controlled
temperature (20–22 °C), fed creatine-free chow and water ad libitum.
All studies were performed in 5–8 month old mice, and conformwith
the Guide for the Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication No. 85–23, revisedand GAMT−/−mice, using different extracellular creatine concentrations (in both groups
th (Cr fed) or without creatine (non-Cr fed) (5 g /kg) supplemented to their diet using
MT−/−Cr; †pb0.05 vs WT.
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1986.
2.2. Creatine uptake measurements in perfused heart
Mice were heparinised and anaesthetised (pentobarbitone
∼ 140 mg/kg body weight i.p.). Hearts were excised, cannulated and
perfused in Langendorff mode at 80 mmHg and 37 °C with Krebs-
Henseleit buffer gassed with 95% O2/5% CO2 (pH 7.4) containing (in
mM): 149Na+, 5.9 K+,1.2Mg2+, 2.25 Ca2+,1.2 SO42−,126.2 Cl−, 0.5 EDTA2−,
25 HCO3−, 1.2 H2PO4−, 11 D-glucose, 1.8 pyruvate and 0.2 lactate.
Contractility was assessed using a ﬂuid-ﬁlled intraventricular balloon
connected to a pressure transducer (AD Instruments Ltd, UK). The end-
diastolic pressure (EDP) was set to ∼10 mmHg.
To determine Michaelis–Menten kinetics of creatine uptake in
hearts from GAMT−/− and WT mice, buffer was supplemented with
either one of three different concentrations of creatine: 100 (n = 4/
group), 500 (n=5/group) and 1000 μM (n=4/group); as previously
described [5], this had no effect on cardiac function and hearts were
stable for the duration of the protocol (up to 1 h). After stabilization,
hearts were perfused with trace amounts of [14C]creatine (Apin
Chemicals Ltd, UK) added to the buffer for 30 min followed by a
15min 14C-label free washout. At the end of each of the perfusion
protocols, hearts were divided into left ventricle, right ventricle and
atria. Tissue samples were weighed and minced with scissors in glass
scintillation vials containing 0.5 mL of a 9:1 v/v solution of hyamine
hydroxide (MP Biomedicals, UK) and water. The vials were incubated
shaking at 60 °C until clear (∼ 3–4 h). To minimize colour quenching of
samples, 100 μL of 30% (w/w) hydrogen peroxide was added followed
byheating at 60 °C for another 30min. After the sampleswere cooled to
room temperature, 10 mL of Cytoscint ES (MP Biomedicals, UK) was
added to each sample followedby vigorousmixing. The vialswere then
allowed to equilibrate in the dark for at least 60min before scintillation
counting.
In a separate set of experiments hearts were used from WT and
GAMT−/− mice that were fed a creatine supplemented diet (5 g/kg) to
test if any differences between the two genotypes were speciﬁc for the
absence of creatine. Creatine uptake in hearts from these mice was
measured in the presence of 1 mM extracellular creatine (n=3/group).
We previously described that our CrT-OE hearts showed a large
variation in CrT-myc mRNA and creatine levels [11]. We expected a
similarly large variation in creatine uptake capacity, which would
make determination of Michaelis–Menten kinetics impossible, as
creatine uptake can only be measured for one extracellular creatine
concentration per heart. Therefore, creatine uptake was only measured
at 1000 μmol/L extracellular creatine in these hearts from CrT-OE
(n=9) and WT (n=5) mice to estimate Vmax.
2.3. mRNA measurements
The relative quantities of endogenous, transgenic, and total CrT,
were measured using the primers shown below. Results were
normalized to the expression levels of the housekeeping gene 36B4
[12], using the double-standard curve method, in which standard
curves spanning ﬁve log dilutions of left ventricular RNA were
constructed for both the 36B4 and CrT primers.Primer SequenceEndogenous CrT F 5′-ACTGGGAGGTGACCTTGTGC-3′
Endogenous CrT R 5′-CGATCTTTCCTGTTGACTTG-3′
CrT c-myc F 5′-TTGGAGTACAGAGCTCAGGA-3′
CrT c-myc R 5′-TCACAGATCCTCTTCTGAGATGAG-3′
Total CrT F 5′-ACTGTGTGGAGATCTTCCGC-3′
Total CrT R 5′-CAGCAAGCTGGTCACATGTG-3′
36B4 F 5′-AGATTCGGGATATGCTGTTGG-3′
36B4 R 5′-TCGGGTCCTAGACCAGTGTTC-3′The endogenous CrT primers were 100% complementary to mouse
CrT mRNA, but had 4–5 mismatches to the transgenic CrT, which is of
rabbit origin. The primer speciﬁcity was validated by RT-PCR analysis
of mouse vs. rabbit heart RNA, and mouse CrT vs. rabbit CrT plasmid
DNA, which showed that mouse CrT was preferentially ampliﬁed
(approximately 100-fold higher ampliﬁcation efﬁciency). The trans-
genic CrT R primer hybridized with the c-myc epitope tag of the CrT
transgene, which ensured transgene speciﬁcity. The total CrT primers
hybridized with regions conserved between the mouse and rabbit CrT
genes. RNA was extracted from frozen left ventricular tissue from
GAMT−/− (n=8) andWT (n=8) mice using the RNeasy Kit (Qiagen, UK),
involving treatment with proteinase K and DNase I and used in RT-PCR
(Qiagen Quantitect SYBR Green RT-PCR kit, Qiagen, UK) using the
Rotor-Gene system (Corbett Research Ltd., UK).
2.4. Western blotting
Approximately 10 mg of frozen, grounded left ventricular tissue
was mixed with 500 μL of extraction buffer (50 mM TRIS, 150 mM
NaCl, 2% SDS, 1 mM DTT, 1 mM PMSF and 1 pellet of protease inhibitor
cocktail (Roche, UK) per 100 mL) and homogenised in a glass tissue
homogeniser for 30 s, followed by 1 h incubation at 4 °C with constant
agitation. The extract was centrifuged at 15,400 g for 10min at 4 °C
and the supernatant was analysed for protein concentration using the
BCA protein assay (Pierce, UK). Equal amounts of protein (40 μg) were
loaded onto SDS-PAGE gels (4% stacking gel, 12% separating gel) which
were run at − 200V for 1 h followed by transfer onto a PVDFmembrane
(GE Health Care, UK) at 200 mA overnight at 4 °C. The membrane was
stained with appropriate antibodies: either anti-MLC2v (Synaptic
Systems), rabbit anti-SGK1 (Abcam, UK), or rabbit anti-phospho-SGK1
(Abcam, UK) followed by goat anti-rabbit-HRP (Santa Cruz, UK). To
conﬁrm equal loading of protein, the membrane was stripped of
antibodies by incubating for 30 min in stripping buffer (2% SDS, 62.5
mM TRIS–HCl pH 6.8, 100 mM 2-mercaptoethanol) at 55 °C, followed
by staining with mouse anti-mouse α-actinin (Sigma-Aldrich, UK)
and goat anti-mouse-HRP (Promega, UK), or rabbit anti-β-tubulin
(Abcam, UK) and goat anti-rabbit-HRP (Santa Cruz, UK). The
antibodies were detected with the ECL Advance chemiluminescence
kit (GE Health Care, UK), and the FluorChem 8800 imager. SGK1
was measured in hearts from GAMT−/− (n=4) and WT (n=4) mice,
phospho-SGK1 in hearts from GAMT−/− (n=3) and WT (n=2) mice,
and MLC2v was measured in hearts from CrT-OE (n=2) and WT
(n=2) mice.
2.5. Biochemical measurements
In CrT-OE mice, transgene expression is cardiac speciﬁc. Therefore,
any extra-cardiac changes in creatine metabolism are not expected.
However, to exclude changes in extracellular creatine levels poten-
tially affecting in vivo myocardial creatine uptake we measured
plasma creatine levels in CrT-OE (n=9) and WT (n=4) mice. Blood
samples were centrifuged at 1800 g for 10min. The supernatant was
used for the determination of creatine plasma concentration by HPLC.
Creatine content in left and right ventricles of CrT-OE (n=9) and WT
(n=6) hearts was also determined by HPLC as described previously
[13]. Due to the radioactive nature of the creatine uptake experiments,
creatine content was measured in a separate set of hearts. Total left
ventricular creatine content was also quantiﬁed by HPLC in the cohort
of CrT-OE mice used for CrT mRNA measurements (n=31).
2.6. Calculation of ΔGCrT and reverse potential
Assuming a stoichiometry of 2:1 for Na+:Cr, the free energy of
creatine transport through the CrT (ΔGCrT) was calculated from
ΔGCrT ¼ 2ΔG þNa þ ΔGCr
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ΔGCrT ¼ 2ΔG þNa þ ΔGCr þ ΔGCl−
where ΔGNa+=RT ln[Na+]i / [Na+]e + zFVm, ΔGCl−=RT ln[Cl−]i / [Cl−]e +
zFVm, ΔGCr = RT ln[Cr]i / [Cr]e, the gas constant (R) is 8.31J mol−1 K−1,
the temperature (T) is 310 K, the intra- and extracellular Na+
concentrations ([Na+]i and [Na+]e) are 10 mM and 146 mM, respec-
tively, z is the valence of the ion, Faraday's constant (F) is 9.65 × 104 J V−1
mol−1, Vm is the membrane potential, the intra- and extracellular Cl−
concentrations ([Cl−]i and [Cl−]e) are 30 mM and 127 mM, respectively,
the extracellular creatine concentration ([Cr]e) is measured in plasma
and the intracellular creatine concentration ([Cr]i) is calculated
assuming total heart protein content to be 0.17 g protein per g wet
weight and intracellular volume tobe 0.5mL/gwetweight. The reverse
potential is Vm when ΔGCrT=0.
2.7. Statistical analysis
Creatine uptake in GAMT−/− and WT hearts was ﬁtted according to
Michaelis–Menten kinetics (uptake=(Vmax×[Cr]e) / (Km+[Cr]e)) using
non-linear regression. Statistical signiﬁcance was assessed using
analysis of variance or a Student's t-test, where appropriate. Statistical
signiﬁcance of differences in the CrT mRNA expression was assessed
with the non-parametric Kruskal–Wallis test with Dunn's correction
for multiple comparisons, as the CrT expression in the CrT-OE group
did not follow Gaussian distribution. Correlation between the
expression of the endogenous and of the transgenic CrT vs. total
creatine was assessed using Pearson's correlation, and results were
considered signiﬁcant at pb0.05. Data are mean±standard deviation.
Differences were considered signiﬁcant at pb0.05.Fig. 2. (A) Left and right ventricular creatine uptake levels in hearts fromwildtype (WT)
mice and from mice overexpressing the cardiac creatine transporter (CrT-OE) using
1 mmol/L extracellular creatine. The average left ventricular creatine uptake levels
amounted to 5.3±1.2 and 14.6±8.5 nmol/min/gww inwildtype (n=5) and CrT-OE (n=9)
hearts, respectively (pb0.001). The average right ventricular creatine uptake levels were
4.8±0.7 and 6.4±2.7 nmol/min/gww in wildtype (n=5) and CrT-OE (n=9) hearts,
respectively (NS). (B) Murine ventricular myosin light chain 2 (MLC2v) protein levels
were approximately 25% lower in right ventricle than in left ventricle in both wildtype
and creatine transporter overexpressing (CrT-OE) hearts.3. Results
3.1. Creatine uptake
Left ventricular creatine uptake kinetics in WT hearts followed
Michaelis–Menten kinetics with a Vmax of 7.2±0.7 nmol/min/gww and
a Km of 179±68 μmol/L, in line with data on creatine uptake in isolated
rat hearts [5]. In contrast, GAMT −/− mouse left ventricles, with
undetectable creatine levels, showed a massive increase in creatine
uptake capacity. As shown in Fig. 1A, apparent Vmax values increased
from 7.2±0.7 in WT to 52.4±2.5 nmol/min/gww in GAMT−/− (pb
0.001). Apparent Km values were reduced from 179 ± 68 inWTmice to
35±13 μmol/L in GAMT −/− mice although the data did not ﬁt
Michaelis–Menten kinetics adequately for the latter to be signiﬁcant.
Right ventricular creatine uptake kinetics were similar to left
ventricular uptake kinetics, but in GAMT−/−, right ventricular uptake
was generally 10–15% lower (pb0.05 vs GAMT−/− LV), as shown in Fig.
1B. Right ventricular apparent Vmax values amounted to 6.3±0.5 in
WTand 41.3±3.5 nmol/min/gww in GAMT−/− (p b 0.001) and apparent
Km values amounted to 22±20 in WT and 163±47 in GAMT −/−
(pb0.05). Contractile function was similar in both groups and the rate
pressure product amounted to 23±9 × 103 and 22±12 × 103 mmHg/
min in hearts from WT and GAMT−/− mice, respectively.
Whenmicewere fed a creatine supplemented diet, the difference in
creatineuptakebetweenWTandGAMT−/−mice essentially disappeared.
As shown in Fig. 1C, cardiac creatine uptake was signiﬁcantly lower in
both ventricles of creatine fed mice compared to those with a creatine-
free diet for both GAMT−/− (pb0.001 for both ventricles)—andWT mice
(pb0.05 for both ventricles). Left ventricular creatine uptake in the
presence of 1mmol/L creatine amounted to 4.8 ± 0.6 and 5.6 ± 0.9 nmol/
min/gww in hearts from creatine fedWTand creatine fedGAMT−/−mice
(NS), respectively. Right ventricular creatine uptake amounted to 4.5±
0.4 and 5.3±1.3 nmol/min/gww in creatine fed WT and creatine fed
GAMT−/− hearts (NS), respectively.
As expected, CrT-OE mice also showed increased left ventricular
creatine uptake levels. As seen in Fig. 2A, creatine uptake in CrT-OE
showed considerable variation between hearts. Average left ventri-
cular creatine uptake levels were 5.3±1.2 and 14.6±8.5 nmol/min/
gww in WT and CrT-OE hearts, respectively (pb0.001). Right
ventricular creatine uptake levels did not differ signiﬁcantly between
groups and amounted to 4.8±0.7 and 6.4±2.7 nmol/min/gww in WT
and CrT-OE hearts (p=0.06), respectively. In CrT-OE hearts, right
ventricular creatine uptake was signiﬁcantly lower than left ventri-
cular creatine uptake (pb0.05). As shown in Fig. 2B, the expression of
MLC2v protein whose promoter drives the CrT-myc transgene
expression, was also lower (approximately 25%, pb0.05) in the right
ventricle than it was in the left ventricle in both CrT-OE and WT mice.
Contractile function was similar in both groups with rate pressure
products of 25±7 × 103 and 24±11 × 103 mmHg/min in hearts from
WT and CrT-OE mice, respectively.
3.2. CrT mRNA levels
As shown in Fig. 3A, the expression of total CrT mRNAwas elevated
by approximately 40% in creatine-free GAMT−/− hearts relative to WT.
However, when the GAMT −/− mice were fed creatine from birth, the
difference between the WT and GAMT−/− CrT mRNA was abolished.
SomeWTmice were also fed creatine, but since their CrT mRNA levels
(0.77±0.09; n=4) did not deviate from those in WT control mice
(0.73±0.15; n=8; p=0.69), the two data sets were pooled.
In hearts from CrT-OE mice, total (endogenous plus CrT-myc) CrT
mRNA levels correlate well with total creatine levels (r=0.67; Fig. 3B),
which is in line with our previously published data showing that CrT-
myc mRNA levels correlate with creatine levels [11]. However, as
shown in Fig. 3C, mRNA levels of the endogenous CrT in these hearts
were not affected by increased total creatine levels (r=0.01).
Fig. 4. (A) Serum and glucocorticoid inducible kinase 1 (SGK1) protein levels analysed
by Western blotting hearts from four GAMT−/− and four wildtype (GAMT+/+) mice. SGK1
levels did not differ between both groups. Equal loading of lanes was conﬁrmed by
stripping the blot, followed by staining for α-actinin. The results were reproduced in a
separate experiment. (B) The phosphorylated, and therefore, active fraction, of SGK1
(phospho-SGK1) was undetectable in the left ventricles of either mouse strain.
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As can be seen in Fig. 4A, the levels of SGK1, a candidate CrT
regulator, in GAMT−/− were unchanged compared to WT controls, and
SGK1/α-actinin levels amounted to 0.21±0.06 inWT and 0.19±0.02 in
GAMT−/− (NS). The phosphorylated, and thus active, form of SGK1 was
undetectable in hearts from mice with both genotypes (GAMT −/− and
WT) (Fig. 4B), suggesting that the WT and GAMT−/− hearts do not
contain phospho-SGK1 or that its level is below the threshold for
detection.
3.4. Creatine levels
Plasma creatine levels were unaltered in CrT-OE mice and were 64±
15 nmol/L inWTcontrols (n=4) and 56±14 nmol/L in CrT-OE (n=9; NS).
Left ventricular creatine levelswere 74±5 and 133±43 nmol/mg protein
in WT controls (n=6) and CrT-OE mice (n=9; pb0.01 vs WT),
respectively. In both strains, right ventricular creatine levels tended to
be lower (by about 7%) than left ventricular levels, a ﬁnding that wasFig. 3. (A) Total CrT mRNA levels in hearts from wildtype mice (WT; n=16), from
creatine-free GAMT−/− mice (n=11), from GAMT−/− mice fed a creatine supplemented
diet (5 g/kg; n=5) and from mice overexpressing the cardiac creatine transporter (CrT-
OE; n=31). Some WT mice were also fed creatine, but since their CrT mRNA levels did
not deviate from those in WT control mice, the two data sets were pooled. ⁎pb0.05;
⁎⁎⁎pb0.001 vs WT. In hearts from CrT-OE mice creatine levels correlate well with total
CrT mRNA (B) but not with endogenous CrT mRNA (C).signiﬁcant in WT controls (69±7 nmol/mg protein; pb0.01 vs LV) but
not in CrT-OE (125±46 nmol/mg protein; NS vs CrT-OE LV; pb0.01 vs
WT RV).
3.5. Free energy change of creatine transport
Using the measured creatine levels we calculated the reverse
potential (i.e. Vmwhen ΔGCrT=0) for creatine transport inWTand CrT-
OE left ventricles. Assuming a stoichiometry of 2:1 for Na+:Cr we
calculated a reverse potential of 3 mV in WT hearts (74 nmol/mg
protein creatine), and of −26 mV in CrT-OE hearts with very high
creatine levels (4-fold normal levels, i.e. 296 nmol/mg protein). When
a stoichiometry of 2:1:1 for Na+:Cr:Cl− was assumed, we found a
reverse potential of 45 mV in WT and of −14 mV in hearts with very
high creatine levels.
4. Discussion
We have demonstrated that in creatine-free GAMT−/− hearts, the
creatine uptake capacity is massively increased to more than 7-fold
that of WT values, while CrT mRNA levels are increased only 1.4-fold,
and that feeding these mice a creatine supplemented diet essentially
abolishes these changes. In addition, we have shown that in hearts
with increased creatine levels due to overexpression of the CrT, the
creatine uptake capacity is increased, but endogenous CrT mRNA
levels do not change with increased intracellular creatine content.
Together, these results suggest that CrT activity can be regulated by
CrTgene expression but that transcriptional control is very limited and
other mechanisms are likely to dominate the regulation of CrT activity
in (patho-) physiological conditions.
There are several lines of evidence to suggest that intra- and
extracellular creatine concentrations alter CrT activity. For example,
chronic increases in plasma creatine concentrations due to creatine
feeding result in a decrease in creatine uptake kinetics and unaltered
myocardial intracellular creatine levels [2]. This ﬁnding is conﬁrmed by
our current observation that creatine uptake in hearts fromWTmice is
reduced when mice are fed a creatine supplemented diet. Similarly,
intracellular creatine depletion by feeding the creatine analogue β-GPA
results in an increased creatine uptake capacity [2]. In human muscle
cells as well as in G8 myoblasts high extracellular creatine concentra-
tions reduced creatine uptake whereas low extracellular creatine
concentrations resulted in increased creatine uptake [14]. However,
the mechanism whereby creatine concentrations alter CrT activity is
poorly understood and literature data regarding CrT regulation should
be interpreted with caution since anti-CrT antibodies used in many
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dehydrogenase complex [15].
Regulation of CrT activity could take place at different levels.
Sandoval et al. [16] characterized the human CrT promoter, and
suggested that its features were compatible with that of a house-
keeping gene. However, the increase in CrT mRNA levels in hearts
from creatine-free GAMT−/− mice, and the reversal of this increase
upon creatine feeding, shows for the ﬁrst time that (in the mouse at
least) the gene is susceptible to transcriptional regulation in response
to a changing physiological environment. And yet an increase of only
40% in CrT mRNA in these hearts is relatively small compared to the 7-
fold increase in creatine uptake, especially considering the extreme
stimulus of zero creatine, and suggests that alterations in gene
expression play only a minor role in regulation of CrT activity. In
support of this conclusion is our ﬁnding that endogenous CrT mRNA is
not downregulated by increased intracellular creatine concentrations
in hearts from CrT-OE mice, and by the fact that we did not ﬁnd any
reduction in CrT mRNA levels after feeding WT mice a creatine
supplemented diet, despite CrT activity being reduced in these hearts.
Finally, the ﬁnding that total CrT mRNA levels in hearts from CrT-OE
mice are higher than those in hearts from creatine-free GAMT−/−mice
despite the much higher creatine uptake capacity in the GAMT−/−
hearts also indicates that CrT activity is primarily subject to post-
transcriptional, rather than transcriptional, regulation.
Such post-transcriptional regulation could occur via CrT protein
modiﬁcation such as phosphorylation since the CrT protein has
putative phosphorylation sites for PKC [17]. In addition, activity of the
closely related transmembrane dopamine transporter is known to be
downregulated by translocation of intracellular dopamine transporter
protein from the sarcolemma to intracellular pools [18], and it is
conceivable that a similar regulating mechanism exists for the CrT.
In Xenopus oocytes expressing the CrT, coexpression of SGK1
resulted in an increase in creatine uptake, showing that SGK1
stimulates CrT activity [7]. However, the unaltered SGK1 levels in
GAMT−/−mice do not suggest that SGK1 is involved in the upregulation
in creatine uptake capacity in these hearts, althoughwe cannot exclude
a difference in SGK1 phosphorylation state in GAMT−/− hearts, which
may have been undetectable with the methodology available to us.
In hearts from mice overexpressing the cardiac CrT we observed
elevated creatine uptakewith a high degree of variation betweenmice.
This is in line with the variation in creatine concentration and CrT-myc
mRNA levels in this, and our previous study [11]. It is interesting to note
that right ventricular (RV) creatine uptake in the CrT-OE hearts was, on
average, 50% lower than left ventricular (LV) creatineuptake. Transgenic
CrT-myc expression is under control of the MLC2v promoter, which is
normally expressed in both ventricles, but differences between
ventricular expression levels for a transgene under the control of the
MLC2v promoter have been reported before [19]. This, and the lower
levels of MLC2v in the RV measured here, probably explains the lower
creatine uptake levels in the right ventricle.
In contrast to rat myocardium where RV and LV creatine levels
were found to be the same [20], RV creatine content was signiﬁcantly
lower than LV creatine content in mouse hearts. However, while
creatine uptake was 50% lower in the RV of CrT-OE mice compared to
LV, the actual creatine concentration was only 6% lower in RV. This
discrepancy can mainly be attributed to hearts with very high LV
creatine uptake, since those hearts showed the greatest difference
between right and left ventricular creatine uptake. A further
discrepancy is that creatine uptake has been measured at up to six
times higher than normal values, while LV creatine concentrations
have never been observed at more than 3–4 times higher than WT
levels, in this or our previous study [11]. Altogether, this suggests that
when the creatine uptake capacity exceeds three to four times the
normal levels, other factors start to play a signiﬁcant role in
determining the myocardial creatine concentration. One potential
factor is whether the CrT can ever operate in reverse to transportcreatine out of the cell. Therefore, we calculated the reverse potential
at which creatine transport out of the cell becomes thermodynami-
cally possible. Our results suggest that reverse transport is not
possible under normal conditions. However, in hearts with very high
creatine levels the reverse potential will be reduced to such an extent
that during the plateau phase of the action potential ‘reverse creatine
transport’ is thermodynamically possible. From previous (unpub-
lished) conscious ECG data in these CrT-OE mice we calculate that the
Q-T interval, which reﬂects action potential duration, can take up to
30% of the cardiac cycle. Thus, it is theoretically possible that reverse
creatine transport could take place during a substantial fraction of the
time in hearts with very high creatine levels.
Although we do not provide direct evidence of CrT reversal, this
theory may well explain our ﬁndings. Thus, we hypothesize that in
hearts with very high LV expression of transgenic CrT, reverse creatine
transport will occur during systole, acting to lower the intracellular
creatine concentration below expected values. This could explain the
dissociation between LV creatine uptake levels and creatine content in
these hearts, as well as the relatively small difference in creatine
concentrations between ventricles despite large differences in
creatine uptake.
GAMT−/− mice accumulate the creatine precursor guanidinoace-
tate, which, although it is capable of being phosphorylated in the
creatine kinase reaction, is a very poor substrate [10]. This implies that
GAMT−/− hearts will have a very high capacity to phosphorylate
creatine, rapidly converting to PCr the instant it is transported into the
cell. This will act to keep the intracellular free creatine concentration
particularly low, facilitating further creatine uptake during the
experiment. One limitation of this study is that we cannot exclude
14C accumulation in myocardium through processes other than CrT
mediated uptake. However, residual extracellular 14C-creatine is
unlikely to be a confounding factor as we used a 15 min washout
period, when in a previous study using rat hearts, no 14C could be
detected in the coronary efﬂuent after 10 min of washout [2].
Regardless, residual extracellular 14C would be similar in absolute
terms for all groups andwould therefore not affect relative differences
between groups, or at worst result in an underestimation. In creatine-
free hearts from GAMT−/− mice, the lack of intracellular creatine
means that the transsarcolemmal creatine gradient is reversed during
the experiment and passive diffusion of creatine into the cells could
potentially contribute to 14C accumulation in these hearts. However,
the high creatine uptake rates in these hearts imply that this gradient
rapidly disappears during the experiment and, therefore, is unlikely to
substantially contribute to the 14C-creatine accumulation.
The large increase in creatine uptake levels in hearts from GAMT−/−
mice show that the heart has an enormous capacity to regulate its
creatine uptake capacity, over a much larger range than known
before. Previously reported changes in creatine uptake capacity are
generally smaller than 50%, in contrast to the N7-fold increase
reported here. The increase is particularly large when compared to
the increase in creatine uptake in hearts from rats fed with β-GPA. In
these hearts intracellular creatine levels were reduced to only 20% of
control, while the Vmax for creatine uptake was increased by 63%. This
suggests that the removal of the last 20% of creatine provides a very
strong signal to increase CrT activity. Our results show that the heart
has the ability to upregulate its creatine uptake capacity to an extent
that is more than required to reverse the reduction in creatine uptake
capacity that is observed in the failing heart. Therefore, it is
worthwhile to unravel the molecular signalling mechanisms activated
by a lack of creatine since it may lead to novel molecular targets for
pharmacological manipulation and restoration of myocardial creatine
content in the failing heart.
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